Use of ROTEM® in Pediatric Cardiac Surgical Patients (PedsROTEM)
Cardiac surgery requiring use of a heart-lung machine, also known as cardiopulmonary bypass (CPB) can induce abnormalities in blood coagulation (clotting) that lead to excessive blood loss during and after operation. While of significant concern in adults, this problem takes on even greater importance in children due to the simple fact that they have a smaller blood volume. It is well known that if a child has previously undergone a heart operation, they are at increased risk of bleeding should more cardiac surgery be required ("reoperation"). The processes regulating blood coagulation are extraordinarily complex, and little is known about the exact mechanisms that contribute to the increased bleeding associated with cardiac reoperation in children. Rotational thromboelastometry (ROTEM®) is a technology that can provide, at the bedside, detailed information about coagulation abnormalities. While not currently approved for general use in the United States, in Europe ROTEM® has been used to guide administration of the blood products in surgery based upon determination of specific coagulation abnormalities. Importantly, there is now evidence that guidelines for transfusion therapy based on ROTEM® reduce transfusion requirements thus decreasing patient exposure to blood products. Whether the use of ROTEM® has potential benefit for pediatric cardiac surgical patients has not been studied. Accordingly, the present study was designed to provide preliminary data comparing coagulation profiles between children undergoing cardiac reoperation to those having primary procedure.
The investigators hypothesize that ROTEM® analysis will detect a pattern of impaired coagulation in children undergoing reoperation. The overall objective of the four assays of ROTEM® analysis therefore, is to provide information that can be used to devise a rational transfusion protocol for pediatric cardiac surgical subjects.
Congenital Heart Defect
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Use of Rotational Thromboelastometry ROTEM® to Characterize Coagulation Abnormalities in Pediatric Cardiac Surgical Patients: A Prospective Pilot Study|
- To obtain pre- and post-cardiopulmonary bypass (CPB) coagulation profiles using ROTEM® in pediatric patients undergoing cardiac surgery with CPB [ Time Frame: Profiles will be collected after induction of anesthesia and before CPB, and after CPB, 5 minutes after protamine adminsitration ]A small blood sample from an already existing arterial line will be taken from the patient at these times and analyzed using the ROTEM® machine.
- To compare ROTEM® coagulation profiles between subjects having primary surgery and those having a reoperation [ Time Frame: 1.3 years ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||September 2010|
|Study Completion Date:||February 2014|
|Primary Completion Date:||February 2014 (Final data collection date for primary outcome measure)|
Primary cardiac surgery
Pediatric patients receiving primary cardiac surgery
Pediatric patients receiving cardiac surgery reoperation
Specific aims of the proposed pilot studies are to:
- Use bedside blood analysis with ROTEM® in pediatric cardiac surgical patients to provide preliminary information on the nature of coagulation abnormalities.
- Compare ROTEM® coagulation profiles between subjects having primary surgery and those undergoing reoperation.
In order to test the study hypothesis, pediatric subjects scheduled to undergo cardiac surgery involving CPB will be recruited for two study groups: a) primary surgery; b) reoperation. For each group, a small amount of blood will be obtained for ROTEM® analysis after induction of anesthesia but before skin incision and again following Cardiopulmonary Bypass, 5 minutes after protamine administration.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01212289
|United States, New York|
|New York Presbyterian Hospital/ Weill Cornell Medical College|
|New York, New York, United States, 10021|
|Principal Investigator:||Aarti Sharma, M.D.||Weill Medical College of Cornell University|